Hormozgan Medical Journal

Published by: Kowsar

Correlation of Allred Score with Tumor Behavior in Breast Cancer Patients Referred to Shahid-Mohammadi Hospital From 2010 to 2017

Ali Atashab Parvar 1 , * , Sara Salari Baghoon Abad 1 , Toba Abbasi 1 and Elham Boushehri 2
Authors Information
1 Pathology Department, School of Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
2 Department of Medical Education, Faculty of Health, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
Article information
  • Hormozgan Medical Journal: 22 (4); e88799
  • Published Online: January 9, 2019
  • Article Type: Research Article
  • Received: January 6, 2019
  • Accepted: January 6, 2019
  • DOI: 10.5812/hmj.88799

To Cite: Atashab Parvar A , Salari Baghoon Abad S , Abbasi T , Boushehri E. Correlation of Allred Score with Tumor Behavior in Breast Cancer Patients Referred to Shahid-Mohammadi Hospital From 2010 to 2017, Hormozgan Med J. Online ahead of Print ; 22(4):e88799. doi: 10.5812/hmj.88799.

Abstract
Copyright © 2019, Hormozgan Medical Journal. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Phi XA, Tagliafico A, Houssami N, Greuter MJW, de Bock GH. Digital breast tomosynthesis for breast cancer screening and diagnosis in women with dense breasts: A systematic review and meta-analysis. BMC Cancer. 2018;18(1):380. doi: 10.1186/s12885-018-4263-3. [PubMed: 29615072]. [PubMed Central: PMC5883365].
  • 2. Kang SY, Kim YS, Kim Z, Kim HY, Lee SK, Jung KW, et al. Basic findings regarding breast cancer in korea in 2015: Data from a breast cancer registry. J Breast Cancer. 2018;21(1):1-10. doi: 10.4048/jbc.2018.21.1.1. [PubMed: 29628978]. [PubMed Central: PMC5880959].
  • 3. Napieralski R, Brunner N, Mengele K, Schmitt M. Emerging biomarkers in breast cancer care. Biomark Med. 2010;4(4):505-22. doi: 10.2217/bmm.10.73. [PubMed: 20701440].
  • 4. Cheang MC, Treaba DO, Speers CH, Olivotto IA, Bajdik CD, Chia SK, et al. Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. J Clin Oncol. 2006;24(36):5637-44. doi: 10.1200/JCO.2005.05.4155. [PubMed: 17116944].
  • 5. Cui X, Schiff R, Arpino G, Osborne CK, Lee AV. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol. 2005;23(30):7721-35. doi: 10.1200/JCO.2005.09.004. [PubMed: 16234531].
  • 6. Lumachi F, Brunello A, Maruzzo M, Basso U, Basso SM. Treatment of estrogen receptor-positive breast cancer. Curr Med Chem. 2013;20(5):596-604. [PubMed: 23278394].
  • 7. Kun Y, How LC, Hoon TP, Bajic VB, Lam TS, Aggarwal A, et al. Classifying the estrogen receptor status of breast cancers by expression profiles reveals a poor prognosis subpopulation exhibiting high expression of the ERBB2 receptor. Hum Mol Genet. 2003;12(24):3245-58. doi: 10.1093/hmg/ddg347. [PubMed: 14570715].
  • 8. Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, et al. Estrogen receptor-positive, progesterone receptor-negative breast cancer: Association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst. 2005;97(17):1254-61. doi: 10.1093/jnci/dji249. [PubMed: 16145046].
  • 9. Daltoe RD, Madeira KP, de Carvalho AA, de Rezende LC, Silva IV, Rangel LB. Evaluation of the progesterone receptor status in breast cancer using three different antibodies: A comparison by Allred score system. Int J Clin Exp Pathol. 2014;7(1):331-9. [PubMed: 24427354]. [PubMed Central: PMC3885488].
  • 10. Qureshi A, Pervez S. Allred scoring for ER reporting and it's impact in clearly distinguishing ER negative from ER positive breast cancers. J Pak Med Assoc. 2010;60(5):350-3. [PubMed: 20527604].
  • 11. Collins LC, Botero ML, Schnitt SJ. Bimodal frequency distribution of estrogen receptor immunohistochemical staining results in breast cancer: An analysis of 825 cases. Am J Clin Pathol. 2005;123(1):16-20. [PubMed: 15762275].
  • 12. Ahmed AR. HER2 expression is a strong independent predictor of nodal metastasis in breast cancer. J Egypt Natl Canc Inst. 2016;28(4):219-27. doi: 10.1016/j.jnci.2016.09.002. [PubMed: 27756653].
  • 13. Sinha S, Nath J. Predictive and prognostic factors in breast cancer and their association with ER PR HER2/neu expression. J Carcinogenesis Mutagenesis. 2016;7(2). doi: 10.4172/2157-2518.1000263.
  • 14. Yamashita H, Yando Y, Nishio M, Zhang Z, Hamaguchi M, Mita K, et al. Immunohistochemical evaluation of hormone receptor status for predicting response to endocrine therapy in metastatic breast cancer. Breast Cancer. 2006;13(1):74-83. [PubMed: 16518065].
  • 15. Horii R, Akiyama F, Ito Y, Iwase T. Assessment of hormone receptor status in breast cancer. Pathol Int. 2007;57(12):784-90. doi: 10.1111/j.1440-1827.2007.02174.x. [PubMed: 17988279].
  • 16. Tang P, Wang J, Hicks DG, Wang X, Schiffhauer L, McMahon L, et al. A lower Allred score for progesterone receptor is strongly associated with a higher recurrence score of 21-gene assay in breast cancer. Cancer Invest. 2010;28(9):978-82. doi: 10.3109/07357907.2010.496754. [PubMed: 20690804].
  • 17. Lee HJ, Park IA, Park SY, Seo AN, Lim B, Chai Y, et al. Two histopathologically different diseases: Hormone receptor-positive and hormone receptor-negative tumors in HER2-positive breast cancer. Breast Cancer Res Treat. 2014;145(3):615-23. doi: 10.1007/s10549-014-2983-x. [PubMed: 24820412].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments